Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Capone

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Journal of Translational Medicine|August 13, 2025
Development of an innovative duplex digital PCR assay for circulating MiRNA ratio quantification in metastatic melanomaAlex De Gregorio, Andrea Sacconi, Chiara Mandoj, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Journal of Translational Medicine|June 3, 2014
Discrepant alterations in main candidate genes among multiple primary melanomasMaria Colombino, MariaCristina Sini, Amelia Lissia, et al.
International Journal of Molecular Sciences|March 6, 2021
Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in MelanomaAnna Barbato, Antonella Iuliano, Mariagrazia Volpe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanomaMaria Colombino, Mariaelena Capone, Amelia Lissia, et al.
International Journal of Molecular Sciences|November 27, 2024
ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced MelanomaDomenico Mallardo, Mario Fordellone, Margaret Ottaviano, et al.
Journal of Translational Medicine|February 24, 2023
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimabDomenico Mallardo, Ester Simeone, Lucia Festino, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 26, 2023
Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestinVittorio Castaldo, Michele Minopoli, Francesca Di Modugno, et al.
Theranostics|November 28, 2022
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanomaCiro Francesco Ruggiero, Luigi Fattore, Irene Terrenato, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Journal of Translational Medicine|August 13, 2025
Development of an innovative duplex digital PCR assay for circulating MiRNA ratio quantification in metastatic melanomaAlex De Gregorio, Andrea Sacconi, Chiara Mandoj, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Journal of Translational Medicine|June 3, 2014
Discrepant alterations in main candidate genes among multiple primary melanomasMaria Colombino, MariaCristina Sini, Amelia Lissia, et al.
International Journal of Molecular Sciences|March 6, 2021
Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in MelanomaAnna Barbato, Antonella Iuliano, Mariagrazia Volpe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanomaMaria Colombino, Mariaelena Capone, Amelia Lissia, et al.
International Journal of Molecular Sciences|November 27, 2024
ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced MelanomaDomenico Mallardo, Mario Fordellone, Margaret Ottaviano, et al.
Journal of Translational Medicine|February 24, 2023
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimabDomenico Mallardo, Ester Simeone, Lucia Festino, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 26, 2023
Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestinVittorio Castaldo, Michele Minopoli, Francesca Di Modugno, et al.
Theranostics|November 28, 2022
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanomaCiro Francesco Ruggiero, Luigi Fattore, Irene Terrenato, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Pageof 7